• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Adicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:04:06 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email
    8-K
    false0001720580NONE00017205802025-05-062025-05-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 06, 2025

     

     

    Adicet Bio, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38359

    81-3305277

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    131 Dartmouth Street, Floor 3

     

    Boston, Massachusetts

     

    02116

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (650) 503-9095

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    ACET

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Description

    99.1

    Press Release of Adicet Bio, Inc. dated May 6, 2025, furnished herewith.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ADICET BIO, INC.

    Date: May 6, 2025

    By:

    /s/ Nick Harvey

    Name:

    Nick Harvey

    Title:

    Chief Financial Officer

     


    Get the next $ACET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACET

    DatePrice TargetRatingAnalyst
    9/30/2024$7.00Buy
    Guggenheim
    9/11/2024Buy → Neutral
    H.C. Wainwright
    6/27/2023Buy → Neutral
    Guggenheim
    6/27/2023Mkt Outperform → Mkt Perform
    JMP Securities
    6/1/2023$20.00 → $6.00Overweight → Neutral
    JP Morgan
    9/21/2022$23.00Overweight
    JP Morgan
    3/31/2022$28.00Outperform
    SMBC Nikko
    3/8/2022$30.00Buy
    Truist Securities
    More analyst ratings

    $ACET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Klickstein Lloyd was granted 5,900 shares, increasing direct ownership by 6% to 108,566 units (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      6/13/25 4:09:59 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chodakewitz Jeffrey was granted 5,900 shares, increasing direct ownership by 50% to 17,700 units (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      6/13/25 4:08:41 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dubin Steve was granted 5,900 shares, increasing direct ownership by 35% to 22,700 units (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      6/13/25 4:07:17 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      1/26/24 7:14:22 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gordon Carl L bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      1/26/24 7:13:05 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schor Chen bought $15,150 worth of shares (11,000 units at $1.38), covered exercise/tax liability with 23,208 shares and sold $15,291 worth of shares (11,000 units at $1.39), decreasing direct ownership by 13% to 153,761 units (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      10/2/23 8:16:14 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York. Details of the event are as follows: Date: Wednesday, June 4, 2025 Time: 4:20 p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is

      5/21/25 4:00:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended M

      5/6/25 4:01:00 PM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per share, the closing price of Adicet's common stock as reported by Nasdaq on April 30, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining

      4/30/25 4:47:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Adicet Bio with a new price target

      Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00

      9/30/24 8:04:57 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Adicet Bio from Buy to Neutral

      9/11/24 7:31:19 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio downgraded by Guggenheim

      Guggenheim downgraded Adicet Bio from Buy to Neutral

      6/27/23 10:07:31 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    SEC Filings

    See more
    • Adicet Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Adicet Bio, Inc. (0001720580) (Filer)

      6/13/25 4:02:01 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adicet Bio Inc.

      SCHEDULE 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      5/15/25 4:15:23 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Adicet Bio Inc.

      10-Q - Adicet Bio, Inc. (0001720580) (Filer)

      5/6/25 4:07:37 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care